Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GTB 5550

Next Previous
Drug Profile

GTB 5550

Alternative Names: B7H3 TriKE™; cam1615B7H3; GTB-5550; GTB-5550 TriKE™

Latest Information Update: 28 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Minnesota
  • Developer GT Biopharma
  • Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Interleukins; Recombinant fusion proteins; Single-domain antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 15 replacements; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple myeloma; Solid tumours

Most Recent Events

  • 14 Aug 2025 GT Biopharma plans to file an IND application for Solid tumours in fourth quarter of 2025
  • 02 Jan 2025 Preclinical development for Solid tumours is ongoing the US
  • 14 Nov 2024 GT Biopharma plans a phase I dose escalation basket trial trial for GBT 5550 in Solid tumours in 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top